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Figure 1: Linear Progression of Breat Tumorigenesis 
(Arpino G, Laucirica R, Elledge RM. Premalignant and In Situ 
Breast Disease: Biology and Clinical Implications. Ann Intern 
M e d .  2 0 0 5 ; 1 4 3 : 4 4 6 - 4 5 7 .  d o i :
10.7326/0003-4819-143-6-200509200-00009) 
The currently accepted stepwise model of breast tumorigenesis 
assumes a gradual transition from normal breast epithelial cells 
to atypical ductal hyperplasia (ADH), to ductal carcinoma in situ 
(DCIS), and then to invasive ductal carcinoma (IDC). 
Percutaneous core needle biopsy (CNB) is the standard 
technique following an abnormal mammographic finding. 
However, CNB is less reliable in differentiating simple ADH 
(sADH) from ADH component coexisted with advanced lesions 
such as DCIS and/or IDC (cADH). Therefore, to identify and 
validate novel reliable molecular biomarkers is essential in 
order to improve the efficiency of therapeutic recommendations, 
as well as to minimize anxiety and unnecessary procedures. 
Our lab has recently characterized two important miRNAs, 
miR-671-5p and miR-638, that are involved in breast cancer 
progression.  
Microdissection and Total RNA isolation from FFPE samples. 
FFPE blocks were microdissected, with each sample containing 
normal, ADH, DCIS, and IDC tissue. Total RNA was isolated using 
the RecoverAll™ Total Nucleic Acid Isolation Kit.  
Collection of patients’ blood and Total RNA isolation before 
CNB procedure. Following IRB protocol, patients with lesions 
detected on mammography elected to donate a blood sample. 
miRNA was isolated using Purelink™ miRNA Isolation Kit 
Examination of miRNA expression by qRT-PCR: qRT-PCR 
was performed to determine the gene expression of both the 
FFPE samples and the blood samples.  
The goal of this research is to analyze and validate the 
candidate miRNAs that may differentiate sADH from cADH 
using FFPE and blood samples following mammography.  
Objectives 
Our data suggest that miRNAs, such as miR-671-5p and 
miR-638, may be potential circulating biomarkers for early 
breast cancer detection following mammography and CNB. 
Results 
Figure 4. Expression of miR-671-5p in serum 
from ADH cases diagnosed by CNB. 
Figure 3. Differential expression pattern of 
miR-671-5p between sADH and cADH. miR-671-5p 
expression was decreased in 78% of sADH cases. 
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Figure 2. Expression of miR-671-5p and miR-638 
d u r i n g b r e a s t c a n c e r p r o g r e s s i o n u s i n g 
microdissected FFPE samples. miR-671-5p and miR-638 
were consistently down-regulated in ADH, DCIS, and IDC vs. 
normal controls. 
